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Abstract: Leishmaniasis is a vector-borne zoonotic disease caused by protozoan parasites of the 
genus Leishmania, which are responsible for numerous clinical manifestations, such as cutaneous, 
visceral, and mucocutaneous leishmaniasis, depending on the site of infection for particular 
species. These complexities threaten 350 million people in 98 countries worldwide. Amastigotes 
living within macrophage phagolysosomes are the principal target of antileishmanial treatment, 
but these are not an easy target as drugs must overcome major structural barriers. Furthermore, 
limitations on current therapy are related to efficacy, toxicity, and cost, as well as the length of 
treatment, which can increase parasitic resistance. Nanotechnology has emerged as an attractive 
alternative as conventional drugs delivered by nanosized carriers have improved bioavailability 
and reduced toxicity, together with other characteristics that help to relieve the burden of this 
disease. The significance of using colloidal carriers loaded with active agents derives from the 
physiological uptake route of intravenous administered nanosystems (the phagocyte system). 
Nanosystems are thus able to promote a high drug concentration in intracellular mononuclear 
phagocyte system (MPS)-infected cells. Moreover, the versatility of nanometric drug delivery 
systems for the deliberate transport of a range of molecules plays a pivotal role in the design 
of therapeutic strategies against leishmaniasis. This review discusses studies on nanocarriers 
that have greatly contributed to improving the efficacy of antileishmaniasis drugs, presenting 
a critical review and some suggestions for improving drug delivery.
Keywords: amphotericin B, drug delivery systems, drug targeting, human leishmaniasis, 
polymeric nanoparticle
Introduction
Leishmaniasis is a parasitic disease caused by Leishmania spp., transmitted to humans 
and animals by species of Phlebotomine and Lutzomyia sandflies. The Leishmania 
parasite has two distinct morphological forms in its life cycle: promastigote and 
amastigote. The sandfly-transmitted flagellated metacyclic promastigotes rapidly enter 
into cells of the mononuclear phagocyte system (MPS) as part of the normal phagocytic 
response. The phagosome formed around the parasites undergoes a process of matura-
tion and remodeling of the membrane and forms a new organelle, the parasitophorous 
vacuole (PV). Within the PV, the promastigotes differentiate into amastigotes, which 
multiply until eruption of the MPS cell (over a period of 4–6 days); the infection 
then spreads further. Having different tropism characteristics, parasites may infect 
either superficial cells or visceral cells. The parasite’s life cycle is completed when 
an uninfected sandfly takes a blood meal from the infected host. Because the infec-
tion involves several overlapping species and sandfly vectors, the taxonomy, ecology, 
epidemiology, and pathogenicity of the disease are complex.1,2
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Leishmaniasis has numerous clinical manifestations, 
depending on which it is classified into three types: 1) cuta-
neous leishmaniasis (CL), the most common; 2) mucocu-
taneous leishmaniasis (ML), which may disseminate to the 
mucosa; and 3) visceral leishmaniasis (VL), also known as 
kala-azar, the most serious form of the disease, which can 
be fatal if not properly treated and could be disseminated to 
several organs.3
Leishmania infantum is responsible for VL infections in 
Latin America and North Africa, while Leishmania donovani 
is responsible for VL infections in areas of the Indian sub-
continent and of East Africa. Although .90% of VL infec-
tions are concentrated in India, Brazil, Bangladesh, Nepal, 
and Sudan,4 a study shows a rapid increase in VL infections 
worldwide and climate change is expected to cause VL to 
severely impact Europe in the near future.5
Treatment failure and relapse rates are particularly high 
in cases of impaired cellular immunity, especially in human 
immunodeficiency virus (HIV) coinfection.6 HIV and 
Leishmania infection mutually reinforce one another, and 
HIV patients are more likely to develop VL (due to reacti-
vation of a dormant infection or clinical manifestation after 
primary infection).
Current chemotherapeutic treatments are successful, to 
some extent, and the major targets pursued by associations 
such as the Drugs for Neglected Diseases initiative (DNDi) 
and the World Health Organization (WHO) in conjunction 
with foundations and pharmaceutical companies, may chiefly 
be summarized as to develop an oral, safe, effective, low-
cost, and short-course treatment for VL and to develop novel 
treatment regimens for patients coinfected with HIV and VL. 
Furthermore, as for all neglected tropical diseases, additional 
control mechanisms and tools are necessary, such as drugs, 
vaccines, reliable diagnostics, vector control agents, and 
control strategies, to eradicate infection.7
Considering the small number of chemotherapeutic 
agents or innovative antileishmanial medicines that are avail-
able, in parallel with the search for more efficient and less 
toxic antileishmanial drugs, including the development of a 
successful vaccine, the push to design stable nanotechnology-
based drug delivery systems (DDSs) is likely to be the main 
strategy in fighting the disease. The use of colloidal carriers 
loaded with active agents is a clear-cut approach, thanks to 
the physiological uptake route of intravenous (iv) adminis-
tered nanosystems (the MPS cells).8 Nanosystems can thus 
lead to high drug concentrations in the intracellular MPS-
infected cells and in the PV; colloidal carriers also protect 
the drug against in vivo degradation.
This review seeks to give an overview of the current 
therapeutic protocols and new approaches involved in the 
search for safer and more active drugs, as well as the strate-
gies employed for choosing appropriate delivery systems to 
produce the next-generation agents for treating VL. Although 
the role of nanotechnology in DDSs for leishmaniasis has 
been reviewed elsewhere,9,10 this review also highlights the 
limits and issues involved in applying modern techniques and 
illustrates the most promising results. In particular, the dif-
ferent strategies, such as their potential, cost, feasibility, and 
limits, were critically evaluated and commented. As in vivo 
studies are imperative for estimating the clinical feasibility 
of a DDS, particular emphasis was given to approaches 
reporting preclinical/clinical data and/or to those showing 
research progress during recent years.
Although alternative immunotherapeutic strategies are 
potentially advantageous, these strategies and nanodevices 
that can be used as promising vaccine carriers were not 
discussed here.9,11
Current chemotherapy
The first therapeutic options were introduced in the early 
1900s for mucocutaneous form, and other treatments have 
been added over the last decade; however, they are not devoid 
of limitations relating to efficacy, toxicity, cost, length of 
treatment, increasing parasitic resistance, and difficulty 
of administration, making treatment a complex issue. The 
principal drugs currently available are antimonials, amphot-
ericin B (AmpB), paromomycin (PM), and miltefosine (MF). 
Table 1, taken from the 2010 WHO report, is presented to 
give a clear view of treatment regimens and their costs (report 
of a meeting of the WHO Expert Committee on the Control of 
Table 1 Price per visceral leishmaniasis treatment
Compound Treatment 
regimen (days)
Drug costa
L-AmpB 10 mg/kg 1 126
L-AmpB 20 mg/kg 2–4 252
AmpB deoxycholate 1 mg/kg 30 20
MF 100 mg/day 28 66–150
PM 15 mg/kg/day 21 15
SSG 20 mg/kg/day 30 56
MA 20 mg/kg/day 30 59
L-AmpB 5 mg/kg + MF 100 mg/day 8 88–110
L-AmpB 5 mg/kg + PM 15 mg/kg/day 11 79
MF 100 mg/kg + PM 15 mg/kg/day 10 30–61
(SSG 20 mg + PM 15 mg)/kg/day 17 44
Note: aFor a patient weighing 35 kg, cost in US dollars (January 2010).
Abbreviations: AmpB, amphotericin B; L-AmpB, liposomal AmpB; MA, meglumine 
antimonate; MF, miltefosine; PM, paromomycin; SSG, sodium stibogluconate.
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Leishmaniases, Geneva, March 22–26, 2010). Several recent 
studies clearly describe the various combination approaches 
that have been used, in the search for the optimal and most 
cost-effective strategy, not only to treat patients but also to 
control infections in countries including Morocco, India, 
Sudan, and Nepal.12–16
Pentavalent antimonials have been used for the past 
several decades to treat VL. At present, two types of organo-
antimony (V) complexes are commercially available: 
Glucantime® (meglumine antimoniate [MA]) and Pentostam® 
(sodium stibogluconate [SSG]). These are the standard first-
line medicines in most parts of the world (.90% overall 
cure rate). Initial treatment of VL should be based on a daily 
injection of 20 mg/kg body weight of Sb(V), and injections 
are usually given for 28–30 days. The cost for the course of 
treatment is ,60 US dollars (Table 1).
The mechanism of action of these compounds, in one 
model, is based on the reductive bioconversion of Sb(V) to 
Sb(III), by the parasite or by the infected host cells, to create 
an active agent Sb(III)–trypanothione conjugate.17 In a 
second model, Sb(V) is the active species, which directly 
exerts activity against Leishmania. Sb(V) is able to act 
selectively against the topoisomerase of the promastigote 
rather than against that of the monocyte.18 Sb(V) is also 
reported to bind ribonucleosides in an environment similar 
to that of lysosomes.19
Unfortunately for first-line antimonials, the development 
of resistance is a primary barrier to successful treatment. The 
resistance mechanism has been found to be multifactorial and 
is principally due to reduced Sb(III) uptake or/and increased 
cell efflux/sequestration through an abnormally high level of 
trypanothione and increased expression of the metalloid-thiol 
pump.20 Resistance to therapeutics has also been imputed to 
different efflux pumps or ATP-binding cassette transporters, 
such as P-glycoprotein and multidrug resistance protein.21
AmpB is a natural antibiotic with a macrolide polyene 
structure and significant antifungal and antiparasitic activi-
ties. Currently, AmpB is widely used to treat systemic 
Candida albicans and Aspergillus fumigatus infections.22 
The mechanism of action of AmpB is based on its binding 
to the ergosterol in the fungus or parasite rather than to 
human cholesterol. In general, AmpB binds to ergosterol 
through a hydrophobic interaction, in a series of events that 
eventually lead to pore formation in the parasite membrane.23 
In clinical trials in India, AmpB formulated with deoxy-
cholate (Fungizone®) was given daily or on alternate days by 
iv slow infusion at a dose of 0.75–1.0 mg/kg/day for 15–20 
doses and was 99% effective.24
To reduce the severe side effects, which include nephro-
toxicity and hematotoxicity, different formulations have been 
developed and are currently available on the market under 
the trade names Abelcet®, Amphocil®, Amphotec® (lipid 
complexes), AmBisome® (liposomes), and Ampholip®.
Used in India and Europe, all of these formulations were 
found to be effective; the liposomal formulation, in which 
the drug is intercalated in a lipid membrane consisting of 
hydrogenated soy phosphatidylcholine (PC), cholesterol, 
and distearoylphosphatidylglycerol, is the most widely used 
against VL. Given at a dose of 3–4 mg/kg/day, for a total dose 
of 15–24 mg/kg, administered to various regimens, AmpB 
liposomal formulation had 90%–98% efficacy in southern 
Europe.25 Shorter treatments are also effective; in India, a 
single-course therapy of 10 mg/kg was found to give a 98% 
cure rate.26 The principal benefit of AmBisome is its reduced 
toxicity to mammalian cells, allowing higher doses to be 
administered, rather than any increase in its antileishmanial 
activity per se. The major drawback of AmBisome is its high 
cost (126–250 US dollars) vs Fungizone (30 US dollars for a 
30-day course of treatment), putting it out of patients’ reach 
in some countries; it is unclear whether this limitation is 
applicable to other geographical areas. Nevertheless, WHO 
and Gilead Sciences have signed agreements to donate hun-
dreds of vials of liposomal AmpB, extending their previous 
agreement until 2021.195 The new 5-year collaboration, whose 
estimated value is 20 million US dollars, includes funding 
that will allow populations affected by VL to benefit from 
enhanced access to diagnosis and treatment.
In a study investigating the extent to which the side effects 
of AmpB were reduced by the use of a lipid emulsion, a pre-
formed AmpB lipid emulsion (ABLE) was compared with 
Fungizone and AmBisome in terms of safety and efficacy.27,28 
Indian clinical trials showed that ABLE was a well-tolerated, 
efficacious, and affordable lipid formulation. In a recent study 
on a population of 500 patients, the efficacy of single day 
infusions of ABLE at 15 mg/kg/day was satisfactory, with 
an initial cure rate of 95.9%, compared to 100% for AmBi-
some. The proportion of patients with no clinical signs and 
symptoms of relapse of kala-azar during 6 months follow-up 
was 85.9% in the ABLE group compared to 98.4% in the 
AmBisome group.28
Resistance to AmpB has been induced in vitro, and a 
study has shown it to be related to the increased cell mem-
brane fluidity occurring when ergosterol is modified to its 
precursor cholesta-5,7,24-trien-3β-ol.29 The modification 
reduced AmpB’s attachment to sterol-modified membranes. 
In clinical isolates of L. donovani, a multifactorial response 
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was observed, in which altered membrane composition, 
ATP-binding cassette transporters, and an upregulated 
thiol metabolic pathway played roles in conferring 
AmpB resistance.30
PM (aminosidine) is an aminoglycoside antibiotic, used 
to treat intestinal infections such as amebiasis and cryptospo-
ridiosis, which was rediscovered as an antileishmanial agent. 
PM has been shown to be effective in Indian VL: a dose of 
15 mg/kg for 21 days administered iv gave a cure rate of 
93%–95%. The mechanism of action of PM in Leishmania 
is not precisely known, but protein synthesis machinery 
has been proposed as the target. Although there are no 
known clinical isolates of PM-resistant strains, a resistant 
L. donovani strain was readily generated experimentally: 
ribosomal proteins were found to be upregulated.31 PM must 
be administered by the parenteral route; however, because 
it undergoes rapid clearance after iv administration, being 
excreted in the urine upon glomerular filtration, treatment 
requires multiple dosages. Adverse effects such as nephrotox-
icity, ototoxicity, and hepatoxicity have been reported.32
MF (hexadecylphosphocholine) was the first, and still 
the only, orally available drug for the treatment of VL.33 
MF belongs to a class of alkylphosphocholine drugs initially 
developed in the 1980s to treat solid tumors. Treatment with 
150 mg/day per .50 kg body weight for 28 days in immu-
nocompetents gave a cure rate of 94% in India and ~90% 
in Ethiopia.34 Its antileishmanial activity involves action on 
several targets; however, no mechanism has been identified 
definitively: alkyl phospholipid metabolism, glycosylphos-
phatidylinositol anchor biosynthesis, signal transduction, 
mitochondrial dysfunction, and immunomodulatory effects 
might be involved.35 Whatever its indication of use, pharma-
covigilance for significant safety issues will remain a priority. 
Furthermore, MF should not be administered in pregnancy 
due to its teratogenicity.33
In India, post-kala-azar dermal leishmaniasis (PKDL) is a 
sequel to VL occurring within a year or up to 32 years after VL 
has been cured; a study suggests that oral MF for 2–3 months 
could be considered as a treatment of choice for Indian 
PKDL.36 MF has a median half-life of ~152 h, which might 
encourage the development of clinical resistance. Furthermore, 
being an oral agent, its improper use in endemic countries 
would increase the risk of resistance and would spread resistant 
parasites where the prevalence of infection is high.37
The risk of emergence of drug resistance in the field is 
exacerbated by the relatively easy production of in vitro 
resistant Leishmania clones, combined with the occurrence 
of relapses in immunocompetent patients, the presence of 
HIV/VL coinfections, and high levels of anthroponotic 
transmission in both Africa and India.38 Combination treat-
ment has the potential advantages not only of shortening the 
treatment duration (thus increasing compliance) and reducing 
the overall drug dose (thereby reducing toxic effects and 
cost) but also of reducing the probability that drug-resistant 
parasites are selected, and thus prolonging the effective life 
of available medicines. Several trials of combinations have 
shown favorable results.39,40 The combination of PM and 
antimonials produced a higher cure rate in VL patients in a 
trial in Bihar, than did antimonials alone, in which the lack 
of response was common.41
Many other compounds are considered to be the second-
line drugs for leishmaniasis, including pentamidine and the 
antifungal azole fluconazole, as well as fexinidazole and oleyl 
phosphocholine (OlPC), with approval status at different 
stages. The diguanidine-based compound pentamidine was 
initially developed as a synthetic analog of insulin. Pentami-
dine has shown high activity against the acute phase of human 
African trypanosomiasis;42 it has attracted renewed interest 
for its use as secondary prophylaxis in HIV-coinfected VL 
patients.43 The drug is given intramuscularly or, preferably, 
by iv infusion. However, pentamidine is now no longer 
recommended as a treatment option for VL. High doses are 
needed to achieve a cure, and irreversible diabetes has been 
reported in 4%–12% of cases.44
The primary action of pentamidine against Leishmania is 
not clearly understood, but the drug’s structural characteristics 
and experimental results suggest that the active transport 
system and the mitochondria are the final sites of inhibi-
tion. A series of experiments showed that it acts as an 
inhibitor of polyamine uptake and the arginine transporter,45 
while other findings indicate the mitochondrial replica-
tion system as possible target (through inhibition of 
topoisomerase II activity).46 Resistance to pentamidine in 
Leishmania has been associated with changes in the concen-
trations of polyamines and arginine within the cell.47
In collaboration with Sanofi, DNDi recently developed 
fexinidazole, a nitroimidazole derivative DNA synthesis 
inhibitor, for the oral treatment of human African 
trypanosomiasis. Fexinidazole has shown potent activity 
against L. donovani in vitro and in vivo in a VL mouse model.48 
A Phase II proof of concept study evaluating the efficacy of 
fexinidazole for the treatment of primary VL was initiated in 
November 2013 in Sudan (FEXI VL 001; NCT01980199); 
this open-label trial was designed to enroll 66 patients. 
DNDi terminated this trial in September 2015 due to lack of 
efficacy. However, the combination of fexinidazole and MF 
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is still in trial.196 Other members of the nitroimidazole class 
of molecules have emerged, and novel products are currently 
in advanced preclinical evaluations.49,50
Nanostructured anti-Leishmania 
delivery systems
The use of DDSs stands as a complementary strategy for 
developing new treatments and combination therapies for 
VL.9 An appropriate DDS can be used in antileishmaniasis 
therapy to produce the necessary high drug concentra-
tion in the intracellular phagolysosome or PV, where the 
Leishmania is hosted. The major challenge in using a small 
drug is the difficulty of enabling it to penetrate inside the 
macrophages: multiple membranes must be traversed by the 
therapeutic agent to reach parasitic target. The nonspecificity 
to  macrophages of current treatments leads to their accumula-
tion in normal, healthy tissues, with prevalent toxicity as side 
effects. Improving the safety/efficacy ratio by delivering a 
high drug concentration at a controlled rate, using an appro-
priate targeting strategy, is an attractive goal that has been 
vigorously pursued.
DDS may also overcome problems relating to the low 
water solubility of drugs and could protect the active mol-
ecule from degradation in biological fluids. Furthermore, 
alternative routes to parenteral drug delivery (eg, nasal, 
pulmonary, and topical) that can improve patient compliance 
are achievable with appropriate DDS. In particular, devel-
oping oral formulations of current chemotherapy options is 
the most attractive prospect, although the lack of treatment 
supervision may lead to patients failing to complete the full 
course of treatment. This is a critical issue, as it may facilitate 
the development of drug resistance in Leishmania. Finally, 
novel materials that are able to become “smart”, capable 
of responding to the physiological environment, can also 
considerably improve drug availability.51
The combination of antileishmanial drugs with nanocar-
riers is emerging as a promising approach, because the tra-
ditional nanocarriers (liposomes and polymer nanoparticles) 
are readily internalized by macrophages in the liver and 
spleen, releasing the drug inside the cell and thus leading 
to a high local concentration, and ultimately killing the 
protozoa. In this connection, the main strategy in treating 
Leishmania is to target the drugs directly to macrophages, 
using appropriate nanosized delivery systems.52 A targeted 
approach entailing modification of the nanocarrier surface 
will also increase parasite selectivity.
Another advantage is the possibility of packing multiple 
payloads in a single carrier, providing a combination therapy 
that may have a synergist effect (overcoming resistance). 
However, the sequencing and scale-up of approaches of this 
type are still very challenging.
The following sections review the recently reported 
research concerning anti-VL nanotechnology, with special 
emphasis on the use of liposomes, polymers, polysac-
charides, metal nanoparticles, and carbon-based materials 
loaded with chemotherapeutics currently used in VL treat-
ment (a schematic presentation of different delivery systems 
is given in Figure 1). Since AmpB is currently the most 
potent antileishmanial agent, the majority of efforts in 
nanotechnology have been focused on this drug. For this 
reason, we pay attention and detail on innovative AmpB 
delivery systems. Table 2 summarizes the principal charac-
teristics and the results obtained.
In particular, one of the most challenging achievements 
is the oral administration of AmpB. This is limited because 
AmpB is absorbed by passive diffusion through the intes-
tinal membrane. However, the process of passive diffusion 
is dependent on drug’s molecular weight and is efficient 
for drugs up to molecular weight 500 Da; efficiency then 
decreases at higher molecular weights. AmpB has a molecu-
lar weight of 924.08 Da, and thus, passive diffusion may be 
expected to be very low.53 Moreover, AmpB is relatively 
unstable at the acidic pH of the gastrointestinal tract, and 
upon oral administration might be degraded prior to absorp-
tion. In addition, it undergoes extensive P-gp efflux from 
the enterocytes, which further limits its oral bioavailability. 
Taken together, these factors lead to very low oral bioavail-
ability of AmpB (~0.3% of the administered dose).
Several nanosystems have also been developed to improve 
the bioavailability of AmpB (for an exhaustive review refer 
Torrado et al54), and some of them, related to VL treatment, 
are reported in the following sections. These delivery systems 
may have several advantages, as they might 1) enhance AmpB 
dissolution and also protect it from the acidic gastric environ-
ment, 2) increase intestinal permeability using either delivery 
systems of an appropriate size to enhance lymphatic uptake or 
carriers able to cross the gastrointestinal barrier, and 3) prolong 
gastrointestinal transit time through the use of bioadhesive 
systems. The biodistribution of AmpB is dependent on the 
type of formulation, and there is a weak correlation between 
drug plasma and organ levels.55 For this reason, AmpB plasma 
levels must be considered in combination with target tissue 
pharmacokinetics. An oral formulation would be of benefit to 
VL patients, but several issues remain to be resolved. 
For completeness, “Novel products with anti-leishmanial 
activity combined into nanocarriers” section comprises 
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DDS loaded with different products with antileishmaniasis 
activity.
Currently, all these experimental compounds, as well 
as the majority of nanostructured systems, have been tested 
in vitro and in animal (mice or hamsters) models. Thus, a 
clear comparison with currently available medicines has to 
be carefully pondered.
Liposomes
Liposomes are small artificial vesicles of spherical shape that 
can be created from cholesterol and phospholipids. Due to 
their biocompatibility, stability, ease of scaling up, and ability 
to carry various molecules as cargo, liposomes are currently 
used as DDS in a range of different treatments. Most lipo-
somal formulations available on the market target cancers. 
Information about this application can be find elsewhere.56
The reticuloendothelial system (RES) is the main site of 
accumulation of liposomes following their systemic admin-
istration, and in the RES, liposomes are mainly cleared by 
resident macrophages. Primary organs associated with the 
RES include the liver, spleen, kidney, lungs, bone marrow, 
and lymph nodes.
The best clinical results in VL treatment, as reported 
earlier, have been achieved with the liposomal formulation 
AmBisome, which allows to load an high concentration of 
AmpB (drug loading [DL] =12.5%) (drug weight/[drug + 
liposomal components] weight) and represents the gold 
standard for novel delivery systems. Over recent years, lipid 
complex formulations of AmpB have been proposed,57 
showing interesting in vitro activity but less efficient than 
AmBisome in in vivo evaluations. More recently, lipo-
somal formulations in which cholesterol was replaced by 
ergosterol, which constitutes 50% molarity of total lipids 
(Kalsome™ 10; Lifecare Innovations Ltd., Gurugram, 
India), have been evaluated.58,59 This change followed the 
in vitro observation that exogenous cholesterol, if added to 
the culture, enhanced the growth of Leishmania promastig-
otes; thus, the absence of cholesterol might make the drug 
more suitable for clearing parasites. Large multilamellar 
vesicles of ~1,000 nm in diameter were obtained and were 
kept separately by sonication. In vivo results confirmed 
Kalsome™ 10 efficacy in a murine VL model without major 
toxic effects. More recently, a possible cell death mecha-
nism in Kalsome™ 10-treated L. donovani was proposed.60 
Interestingly, the component of the liposomal formulation 
induced apoptotic-like cell death in L. donovani parasites, 
demonstrating its antileishmanial function.
A number of older anti-Leishmania antimonials, formu-
lated in liposomes, have been investigated, starting in 1977.61 
Liposomes with different surface charge (anionic and neu-
tral) were subsequently tested,62 but only recently, a robust 
effective treatment against infection with SSG-resistant 
Leishmania parasites in mice has been demonstrated, using 
cationic PC–stearylamine liposomes. When the charged 
Figure 1 Schematic representation of different classes of antileishmanial nanometric delivery systems.
Note: The character size (also bold type) evidences the number of publications related to each system.
Abbreviations: PCL, poly(caprolactone); PGA, poly(glycolic acid); PLA, poly(lactic acid); PLGA, poly(lactide-co-glycolide).
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phospholipids were encapsulated in liposomes, their binding 
to macrophages was shown to be greatly enhanced.63
To improve liposome stability and enhance blood cir-
culation time, sterically stabilized liposomes have been 
introduced: the addition of polyethylene glycol (PEG) to the 
liposome surface slows removal from the blood, improving 
half-life (eg, Doxil®).64 PEGylated and uncoated liposomes 
bearing MA in VL-infected dogs were compared;65 the 
former were more effective, although a mixed formulation 
of PEGylated and conventional liposomes showed greater 
activity, than either single formulation, for parasite elimina-
tion in the spleen and bone marrow.
Other drugs commonly used as anticancer agents 
have been encapsulated in sterically stabilized liposomes: 
camptothecin66 and, more recently, doxorubicin have been inves-
tigated to integrate MA treatment, so as to decrease the resis-
tance of Leishmania against currently available drugs.67
From the toxicology standpoint, liposome-mediated 
delivery leads to greatly increased and prolonged concentra-
tions of antileishmanial drugs in the liver and spleen. This is 
an advantage in a disease such as VL, where macrophages are 
the target of the therapy, but the macrophages might already 
be impaired by the infection, and high tissue accumulation 
may lead to severe side effects.68
In a study aiming to improve the oral bioavailability 
of AmpB, the antileishmanial activity of two nanocarriers 
was compared: soya lecithin (Lec)-based biodegradable 
nanocarriers and liposomes. The surface of the Lec–AmpB 
nanoparticles was modified with PEG and Tween 20 to 
further improve their stability and biological activity. PEG 
nanoparticles showed more promising antileishmanial 
activity, possibly because of their better interaction with 
biological systems and membranes.69
To further increase the specificity of action to the dis-
eased area, liposomes decorated with specific ligands have 
also been developed. This strategy offers a vast potential 
for site-specific delivery of drugs to designated cell types 
or organs, which selectively express or overexpress specific 
ligands (eg, receptors and cell adhesion molecules) at the site 
of the disease.70 However, their real therapeutic advantage 
over nontargeted liposomes is still debatable, with conflicting 
results being reported; no targeted liposomal product has yet 
reached the market.
The targeting approach was applied to liposome- 
encapsulated AmpB, by decorating the particle surface with 
the naturally occurring macrophage activator tetrapeptide, 
tuftsin (Thr–Lys–Pro–Arg). Increased in vivo antileish-
manial activity vs standard liposomes was observed and T
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appeared to be due both to improved drug tolerance of the 
liposomal formulation (like that of AmBisome but with a 
DL of 2%) and to the increased specific uptake of tuftsin by 
the macrophages.71
C-type lectin receptors (CLRs) are highly conserved 
pattern recognition receptors with carbohydrate recogni-
tion domains that bind sugars (eg, mannose, fucose, and 
N-acetylglucosamine), present on the surface of many 
pathogens.72 In particular, the mannose receptor (also called 
CD206) was the first reported member of a family of four 
endocytic CLRs receptors; it plays a role in the clearance 
of endogenous glycoproteins and in pathogen recognition/
antigen presentation. The targeting of pattern recognition 
receptors on macrophages offers the advantage of triggering 
specific signaling pathways, thus inducing a tailored and 
robust immune response. Antileishmanial drugs have been 
encapsulated in mannosylated or fucosylated liposomes to 
target the corresponding receptors expressed by macrophages; 
they demonstrated successful treatment of experimental leish-
maniasis in a hamster model.73 Furthermore, a biodistribution 
study clearly showed that uptake of mannosylated liposomes 
in the liver and spleen was higher than either free AmpB 
solution or cationic liposomal formulation, indicating that 
active targeting to the RES occurred.73
Nanoemulsions (Nes) and niosomes
NEs are mixtures of two normally immiscible liquids that 
are stabilized by using a surfactant (emulsifier). The addition 
of surfactant is critical for the creation of small droplets 
(~100 nm) as it decreases the interfacial tension. The emul-
sifier also plays a role in stabilizing NE through repulsive 
electrostatic interactions and steric hindrance.74 Lipid AmpB 
formulations potentially suited to oral administration have 
been developed based on mono- and diglycerides with or 
without a lipophilic derivative of vitamin E, d-α-tocopheryl 
polyethylene glycol 1000 succinate (TPGS), as an alternative 
to the less temperature-stable monoglyceride. The formula-
tion, named ICo-010, retained AmpB in simulated gastric and 
intestinal fluids and exhibited a significant antileishmanial 
activity in a VL-infected murine model.75,76 ICo-010, cur-
rently being developed by iCo therapeutics, was granted 
orphan drug status by the FDA, but recent data from the 
company website do not show any further improvement from 
preclinical evaluations.197
A NE loaded with doxorubicin (NE–DOX) was fur-
ther grafted with phosphatidylserine (PS) to enhance the 
cellular uptake.77 There was significant improvement in 
activity with PS–NE–DOX on the spleen parasitic burden 
in Leishmania-infected hamsters, in comparison to uncoated 
NE or free drug.
Niosomes are vesicles consisting of nonionic surfactants 
with cholesterol. These are biodegradable, somewhat less 
toxic and more stable than liposomes, and relatively low in 
cost, making them an alternative to liposomes. These particu-
lar characteristics make niosomes promising candidates for 
commercial manufacturing.78 In an early study on delivery 
systems for VL, niosomal SSG was found to be more effec-
tive than liposomal vesicular formulations or than free drug, 
against experimental murine VL.79 More recently, the effect 
of itraconazole niosomes on the in vitro susceptibility of 
L. tropica was demonstrated.80 Entrapment efficacy of AmpB 
into niosomes has been also reported.81
Lipid cochleates
An interesting approach to prepare lipid systems for oral 
delivery is that of nanocochleates, cigar-shaped nanostruc-
tures composed of negatively charged lipid bilayers (usually 
PS) bridged by a divalent cation, normally calcium.82 Calcium 
induces dehydration of the interbilayer domains, and conse-
quently, the amount of water in this region is low, allowing 
better encapsulation efficiency of hydrophobic drugs, which 
have a high affinity for the hydrophobic interior of the lipid 
bilayers. AmpB is an ideal model for hydrophobic drugs. 
Nanocochleates containing AmpB or AmpB deoxycholate 
were in vitro tested against L. chagasi, and results showed 
similar activity.83,84 Lipid cochleates containing both AmpB 
and MF were also produced, and the incorporation stability 
was estimated.85 Some clinical trials for VL were initiated on 
the basis of the results obtained with an oral nanocochleate 
formulation of AmpB (Bioral® Amphotericin B), which 
reached Phase I development in the USA for the treatment of 
mycoses, but nowadays, the research appears to be discontin-
ued. However, Matinas BioPharma is developing MAT 2203, 
comprising nanocochleates of AmpB for oral administration 
in treating asperigillosis.198
Solid lipid nanoparticles (SLNs)
SLNs are nanospheres made from solid lipids, with size in the 
range of 50–1,000 nm. They consist of a solid lipid matrix, 
ie, glycerides, fatty acids, and waxes, stabilized by physi-
ologically compatible emulsifiers, such as phospholipids, 
bile salts, Tween, polyoxyethylene ethers, and polyvinyl 
alcohol. The lipids used in their production are solid at 
room temperature, and most of them have approved status, 
eg, Generally Recognized as Safe (GRAS), due to their 
low toxicity.86
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Chitosan-coated SLNs loaded with AmpB have been 
developed for immunoadjuvant chemotherapy of Leish-
mania infections. The in vitro antileishmanial activity 
revealed that chitosan-coated AmpB–SLNs were markedly 
more potent than commercial formulations (AmBisome 
and Fungizone). Furthermore, cytotoxic evaluation in 
macrophages and acute toxicity study in mice evidenced a 
better safety profile of the formulation compared to mar-
keted products.87
More recently, PM was incorporated into SLN made of 
stearic acid and Tween 80, and both characterization and 
in vivo data were reported.88,89 As with liposomes, it has 
been attempted to increase the uptake by macrophages by 
targeting to mannose receptors. Mannose-coated lipid nano-
particles of AmpB showed higher liver uptake and promising 
antileishmanial activity.90 Interestingly, SLN can also be 
used to improve oral administration protocols (AmbiOnp 
formulation),91 although this has not yet been applied in VL 
therapy. The loading of AmpB in the nontoxic superaggre-
gated form results in enhancing the oral bioavailability and 
increasing their safety profile.91
To reduce the side effects that limited the use of MF, 
delivery in lipid nanoparticles has been proposed.92 MF 
formulations were prepared using glycerin, cottonseed oil, 
oleic acid, cholesterol, and the emulsifiers, such as egg PC 
and Tween 80. A reduction in epithelial irritation in the gas-
trointestinal tract was observed in an in vivo study performed 
in Balb/C mice. Compared to the free drug, the formulation 
reduced in vitro hemolytic action and cytotoxic activity 
against macrophages and resulted in comparable level of 
in vitro cytotoxicity against promastigote and amastigote 
forms of L. chagasi.92
Polymer nanoparticles
Polymer nanoparticles may be of value in treating infec-
tious diseases such as leishmaniasis, since their small 
size enables them to pass through biological barriers 
upon parenteral administration, also enhancing cellular 
uptake and enabling therapeutic agents to be delivered 
to infected tissues.10 Polymer nanocarriers can be modu-
lated to give them advanced physicochemical properties, 
such as increased bioavailability, and precisely defined 
biodegradability, affording release of the encapsulated 
drug. Polymer system may consist of either a polymeric 
matrix (nano- or microspheres) or a reservoir system 
(nano- or microcapsules). Several different synthetic 
polymers can be used to prepare nanoparticles, includ-
ing poly(lactic acid) (PLA), poly(glycolic acid) (PGA), 
poly(lactide-co-glycolide) (PLGA), poly(caprolactone) 
(PCL), and poly(cyanoacrylate) (PCA).93 However, natural 
protein polymers, such as albumin and gelatin, and polysac-
charides, such as chitosan, alginate, and starch, have also 
been described as candidates for the delivery of particle-
based antileishmanial systems.94 Other polymers, such as 
PEG and N-(2-hydroxypropyl)methacrylamide (HPMA), 
have been used predominantly to produce polymer–drug 
conjugates in the form of macromolecular prodrugs. In this 
approach, the release mechanism entails splitting the linker 
between the polymer and the bioactive agent.
Concerning synthetic polymers, the first studies involved 
the use of PCA and PCL, loading different drugs with inter-
esting results.95 However, in recent years, PLGA has been 
one of the most attractive polymeric candidates, used to 
fabricate devices for drug delivery and tissue engineering 
applications.96 Currently, 15 FDA-approved PLGA-based 
drug products are available on the US market.199
Different research groups have investigated AmpB-
loaded PLGA nanoparticles. In particular, the efficacy of 
PLGA nanoparticle-encapsulated AmpB was compared 
to free drug or marketed formulations against intracellular 
L. infantum amastigotes as well as promastigotes. One 
nanoparticle formulation was more effective than AmBi-
some and, at the same time, less cytotoxic and hemotoxic.97 
Although very promising, especially as an antifungal agent, 
no further in vivo clinical applications have since been 
reported.
AmpB has been entrapped in PLGA nanoparticles to improve 
its oral bioavailability and to reduce its nephrotoxicity.53 
The addition of the stabilizer TPGS permitted the forma-
tion of stable nanoparticles of ,200 nm in diameter. It is 
worth remembering that TPGS, reported as a P-gp efflux 
inhibitor, is currently approved by the FDA for use as an 
excipient in various nanoparticle formulations and also as a 
solubilizing and emulsifying agent for poorly soluble com-
pounds to improve their absorption and bioavailability.98 The 
AmpB–PLGA formulation containing TPGS reduced drug 
nephrotoxicity on administration by either the oral route 
or the iv route compared with Fungizone. The relative oral 
bioavailability of AmpB was found to be about eight times 
higher when it was formulated in polymer nanoparticles 
than when it was administered as Fungizone.99 Further 
study on in vivo activity has only been reported for pulmo-
nary aspergillosis.100
MF loaded in PLGA–PEG nanoparticles also showed a 
fourfold increase in in vitro activity and in in vivo antileish-
manial efficacy and bioavailability vs free drug.101
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Lipid–polymer hybrid nanoparticles (LPNPs) loading 
AmpB with the anionic core composed of PLGA polymer and 
TPGS surfactant and the shell made of cationic stearylamine 
lipid have also been prepared.102 Stearylamine was selected 
for its cationic nature, biocompatibility, benign antiprotozoal 
activity, and immunopotentiation strength. LPNPs containing 
an interesting amount of AmpB (DL 9.8%, w/w) were 
reported. Receptor-mediated LPNP identification ensures 
considerable uptake into the macrophage cells and RES 
organs (spleen, liver, and so on), while uptake by the kidneys 
is very low. Furthermore, the positive charge of LPNPs allows 
them to bind to negatively charged sialic acid molecules on 
the macrophage surface, resulting in adsorption-mediated 
endocytosis. In vivo experiments demonstrated significantly 
stronger parasite growth inhibition (89.4%) in patients treated 
with AmpB–LPNPs than in those treated with carrier without 
stearylamine (63.6% inhibition), whereas 69.3% parasite inhi-
bition was observed with the AmBisome formulation.102
With regard to the active targeting approach, mannose-
bearing PLGA nano/microparticles have been designed to 
further improve macrophage targeting of antileishmanial 
agents. Mannose-grafted PLGA nanoparticles, with and 
without a PEG spacer, are reported to target AmpB;103 the 
presence of PEG spacer resulted in a more efficient inhibition 
of parasites in comparison to both the one without spacer 
and the free drug. Furthermore, both drug–polymer inter-
action and drug miscibility in the polymer affect the drug 
content of polymer nanoparticles. The PLGA hydrophobic 
core facilitates the loading of amphiphilic AmpB. The 
polymer slow precipitation, due to the slow rate of solvent 
removal, allowed more time for drug molecules to partition 
into the aqueous phase, leading to low % encapsulation 
efficiency. However, in the engineered version of polymer 
nanoparticles, in which mannose was directly linked to 
PLGA (M–PNPs) or to the edge of PEG (M–PEG–PNPs), 
an increased entrapment efficiency was observed, probably 
due to the higher drug–polymer miscibility, permitting the 
enhanced drug incorporation.103 The significant rise in drug 
content in M–PNPs and M–PEG–PNPs might be due to the 
stronger drug–polymer interaction (between the hydroxyl 
group of mannose and PEG and the amine group of AmpB) 
and to the high miscibility in the case of amphiphilic AmpB. 
Another study suggested that the acidic end-group of PLGA 
is responsible for drug incorporation and that increased chain 
length may increase the drug–polymer interactions, leading 
to improved drug incorporation efficiency.104
More recently, carbohydrate (mannose, mannosamine, 
and mannan)-functionalized PLGA nanospheres loaded with 
AmpB have been investigated in the treatment of murine 
VL.105 The uptake of mannan-coated nanoparticles (MNs) by 
macrophages was elevated. Furthermore, a single injection and 
a 1-week course of treatment with MN–PLGA AmpB nano-
particles were sufficient to achieve a significant decrease in 
the visceral organs parasite load, although AmpB loading was 
only 0.58% (w/w). The successful results were probably due 
to increased production of cytokines relevant in VL infection, 
such as INF-gamma, and nitric oxide (NO), which plays a key 
role in the organism’s defense against parasite infection.105
Polymeric nanosystems are also feasible as carriers 
for multiple drugs. In a recent study, PLGA nanoparticles 
loaded with AmpB and doxorubicin and further coated with 
chitosan as a macrophage targeting agent were developed. 
Chitosan-coated nanoparticles provide a signal for special-
ized phagocytes, because chitosan recognition involves 
multiple macrophage surface receptors inducing the drug 
internalization into cells. Furthermore, this system dem-
onstrated slow drug release to macrophages, with minimal 
hemotoxicity and tissue toxicity.106 Currently, no in vivo data 
on VL infected rodent models are available.
AmpB was recently targeted by PLGA nanoparticles 
using a coating with glycoprotein lactoferrin (Lcf).107 Lcf is 
an 80 kDa iron-binding glycoprotein with a single polypep-
tide chain of ~700 amino acids that provides several potential 
N-glycosylation sites. These sites of Lcf are recognized by 
the group of CLRs, ie, mannose receptors, which present 
as biomarkers on the monocyte/macrophage and dendritic 
cell surfaces. In vivo tests demonstrated significant in vivo 
antileishmanial activity of Lcf–PLGA–AmpB, compared 
with nontargeted and commercial formulations, as well as 
lower nephrotoxicity, attributed to the slower drug release. 
This might permit the administration of much higher drug 
doses, leading to increased efficacy in VL treating. It is worth 
noting that peptide fragments derived from Lcf, such as 
lactoferricin, exerted interesting activity against L. donovani 
promastigotes.108 AmpB encapsulated into PEG–PLGA 
nanoparticles, further decorated with anti-CD14 antibod-
ies, was recently evaluated for macrophage localization 
improvement.109 CD14 is mainly present on macrophages 
surface and, to a lesser extent, on neutrophils and dendritic 
cells. Interestingly, evaluations on promastigote and amas-
tigote revealed that the inhibition efficiency of nanoparticles 
was higher than that of free drug.
Polysaccharide polymers
Polysaccharides are ideal candidates for drug delivery and 
biomedical applications, as they are easily obtained from 
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natural sources. Examples of polysaccharides of plant origin 
include starch, cellulose, hemicellulose, hyaluronic acids, 
alginate, and guar gums, whereas polysaccharides originating 
from animals include chitin and chondroitin sulfate.110 Natural 
polysaccharides have been evaluated for their ability to act 
as antileishmanial agents, in some cases based on their use 
in traditional medicine111 and in others from exploring novel 
sources such as marine macroalgae, which contain sulfated 
polysaccharides with antileishmanial activity.112 Polysac-
charides with different structures act by different mecha-
nisms in macrophages:113 sulfated heterorhamnan, iota-/
nu-carrageenans, and arabinogalactan polysaccharides dem-
onstrated significant macrophage activation and a subsequent 
inhibition of intracellular amastigotes of L. amazonensis. The 
antileishmanial effects of the polysaccharides occurred by 
different mechanisms: for sulfated polysaccharides, this may 
be an expressive increase in NO production by macrophages, 
while for arabinogalactan, it may be attributed to stimulation 
of O
2
•− and TNF production.113
Polysaccharide polymers have also been used to deliver 
vanadium complexes, which are reported to be highly active 
metal-based drugs against a variety of trypanosomatids, 
including Leishmania species.114 The immunomodulatory 
effects of the polysaccharides arabinogalactan, galactoman-
nan, and xyloglucan, as well as their oxovanadium (IV/V) 
complexes, were evaluated on peritoneal macrophages exhib-
iting significant leishmanicidal activity (~60%–70%). The 
mechanism of action appears to be due to increasing levels 
of IL-1b and IL-6 released by macrophages.115 Vanadium 
complexes of stilbene demonstrated leishmanicidal activity 
in promastigote forms of L. amazonensis, inducing reac-
tive oxygen species (ROS) production and NO-dependent 
microbicidal action.116
Biopolymers such as chitosan and sodium alginate are 
potent macrophages activators, inducing the release of a 
range of cytokines and cytotoxic agents.117–119 Development 
of a biocompatible polymers formulation, which enhances 
immunological responses, might thus provide a new approach 
to improve leishmaniasis treatment. Naturally occurring poly-
saccharides, such as chitosan and alginate, have been utilized 
to deliver antileishmanial agents in nanoparticles. Nanometric 
AmpB-encapsulated chitosan nanocapsules (CNC–AmpB) 
have been formulated using a polymeric deposition technique 
mediated by NE template fabrication.120 The lipid core of 
the nanocapsule consisted of surfactant, glycerol, soybean 
oil, and soya lecithin. Enhanced efficacy of CNC–AmpB 
is likely due to active macrophage targeting by N-acetyl-
glucosamine unit of chitosan content of CNC, recognition 
being mediated by major histocompatibility complex class I 
and II, Fc receptors, and mannose receptors. The same team 
improved the targeting capability of chitosan, using manno-
sylated chitosan (Mnos-CS) copolymer, subsequently formu-
lated in a nanocapsule system (MnosCNc) for the delivery of 
AmpB.121 Using nanocapsules, DL of 9%–10% (w/w) was 
obtained. In vivo results showed that more drug was delivered 
by mannosylated nanocapsules than by CNC or plain AmpB 
in both liver and spleen.
Polyelectrolyte complexes (PECs) are formed by inter-
actions between two macromolecules bearing oppositely 
charged groups. Encapsulation of a drug during formation of 
PECs has shown great promise for preparing drug delivery 
carriers. For this purpose, the native positively charged 
polymer chitosan, and chondroitin sulfate, of negative 
charge was used to load AmpB,122 resulting in a good DL 
(11%, w/w). In evaluating the antileishmanial activity, it 
was observed that chitosan itself presented activity and a 
synergistic interaction between chitosan and chondroitin sul-
fate also occurred. The activity of AmpB nanoparticles was 
similar to those with pure AmpB; however, the cytotoxicity 
of the nanoparticle formulation was approximately one-tenth 
that of pure AmpB. Neither pure chitosan nor chondroitin 
sulfate, or the nanoparticles, presented any significant mac-
rophages toxicity.122
Chitosan was also chemically modified into glycol chi-
tosan stearate, an amphiphilic copolymer that forms carriers 
with a hydrophilic shell and a hydrophobic core comprising 
stearic acid.123 By increasing the rigidity of the bilayer of 
so-called lipo-polymerosomes (L-Psomes) using cholesterol, 
a very large amount of AmpB was loaded (25%), exploiting 
the hydrophobic interaction with the stearic acid chain. The 
AmpB–L-Psomes proved to be a biologically safe and stable 
delivery system, with improved efficacy compared to com-
mercial formulations; they can thus be proposed as an alter-
native low-cost product. A further study exploited a surface 
interaction between chitosan and sodium alginate (natural 
polymer with anionic charge) to stabilize the nanoparticles, 
maintaining the high AmpB loading (22%).124 The biopoly-
mers sodium alginate and chitosan are potent macrophage 
activators, inducing the release of different cytokines and 
cytotoxic agents.118 In vivo study demonstrated that L-Psomes 
facilitated the AmpB uptake in RES-rich organs and showed 
that AmpB remains in the tissues for prolonged periods, 
followed by slower distribution of the drug into the blood 
stream. Increased tolerance to AmpB was also observed.118
Alginate has also been used as active coating of a lipo-
somal AmpB preparation117 and, more recently, of doxorubicin 
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loaded in an NE (soybean oil with Tween as surfactant and 
protamine sulfate).125 This treatment strategy is based on the 
immune response modulation, combined with chemotherapy, 
to improve efficacy during infection.
Ionic amphiphile biovectors, first reported by Loiseau 
et al,126 comprised anionic lipids (dipalmitoyl phosphatidyl 
glycerol) included in a cationic cross-linked maltodextrin 
matrix, used as reservoir for AmpB. The nanoparticles of 
100 nm were loaded with 20% (w/w) AmpB and demon-
strated a high stability. The in vitro and in vivo activities 
remained in the same dose and concentration range as 
Fungizone and AmBisome, suggesting that their interaction 
with host cells, their uptake, and intracellular distribution 
were efficient, although the formulation is slightly less active 
and safe than AmBisome.126 Although in the early devel-
opment stage, ionic amphiphile biovectors have not been 
further improved or described. However, hydroxypropyl-γ-
cyclodextrin was used to solubilize AmpB solution (AmpB–
dextrin solution) by inclusion; it was then formulated into 
nonionic surfactant vesicles (NIVs) (consisting of a 3:3:1 
molar ratio of mono-n-hexadecylether tetraethylene glycol 
to cholesterol to dicetylphosphate). The antileishmanial 
activity of NIV and chitosan-coated NIV was compared 
with that of commercial AmpB formulations.127 It has been 
shown that the pulmonary route is not only suitable for lung 
conditions but can also be used to target the liver: treatment 
with an NIV formulation of AmpB significantly reduced 
L. donovani liver parasite burdens in treated mice and was 
also effective at reducing Aspergillus levels in the lungs.100 
Furthermore, a reduced toxicity in L. major-infected mice 
after several (15) doses indicated that both formulations, as 
well as the pulmonary route, minimized systemic exposure 
to AmpB.
Polymeric micelles
Polymeric micelles are nanoscopic core/shell structures made 
up of amphiphilic block copolymers. Both the intrinsic and 
the modifiable properties of polymeric micelles make them 
particularly well suited for drug delivery purposes.128 Among 
the polymers used for micelle preparation, poloxamers 
(α-hydro-ω-hydroxypoly[oxyethylene]
a
 poly[oxypropylene]
b
 
poly[oxyethylene]
a
 block copolymers) present interesting 
behavior and have been applied in a wide range of biomedical 
and pharmaceutical industries. Particularly, poloxamer in 
aqueous media exhibits micellar structures, which can convert 
into gel-like structures depending on their length, concentra-
tion, and temperature. In the search for new delivery systems 
to treat tegumentary leishmaniasis, AmpB-containing a 
polymeric micelle system (namely AmpB/M) was developed 
using poloxamer P407 (Pluronic® F127) and its in vitro and 
in vivo potency against L. amazonensis was evaluated.129 
When administered by subcutaneous injection in mice, the 
AmpB/M formulation turns into a semirigid gel on contact 
with local tissue, creating a reservoir system and keeping the 
drug in the extracellular space; this allows it to act against 
parasites at the local infection site. Over time, as the gel 
matrix is diluted by body fluids and phagocytosis, the drug 
is gradually released into systemic circulation, enabling its 
systemic action to be controlled.
A poloxamer P407-based paramomycin-containing 
micelle nanogel system has been evaluated. The system was 
tested for in vivo tolerance, ex vivo cytotoxicity on cells, 
and antileishmanial activity against promastigotes. The 
results showed the product to possess negligible toxicity 
and effective antileishmanial activity against L. major and 
L. infantum promastigotes. It was concluded that the for-
mulation provides controlled, effective, and safe delivery 
of paramomycin in mice.130
An interesting approach to obtain stable micelles with high 
DL is based on the self-assembling ability of prodrugs with 
amphiphilic properties. Regarding pentavalent antimonials, 
the use of nonionic surfactants as complex agents has been 
investigated.131 The formation of an amphiphilic antimony 
(V) complex using N-alkyl-N-methylglucamide (with carbon 
chain lengths of 8 and 10) produced stable nanodispersions 
(~115 nm). The most significant advantages of the system 
were its great solubility in water, its superior bioavailability, 
and sustained drug release properties. These results were 
much better than those obtained with a cyclodextrin-based 
oral formulation of MA proposed by the same group.132 
Micelles of the amphiphilic antimony (V) complex may 
also offer a possibility for solubilizing lipophilic drugs and 
achieving oral coadministration of anti-VL drugs.
Inorganic compounds as delivery systems
The majority of nanoparticles of pharmaceutical interest 
are made of organic polymers (biodegradable or not), but 
inorganic systems, as well as organic–inorganic hybrid 
materials, are now also receiving considerable attention in 
the pharmaceutical field. Mesoporous silica nanoparticles, 
hydroxyapatite nanostructures, metallic nanoparticles such 
as Fe
3
O
4
, gold, and silver nanoparticles, and carbon-based 
nanostructures (nanotubes, graphene, nano-onions, and 
horns) exhibit several interesting features and enable dif-
ferent functionalities (eg, diagnostic and therapeutic) to be 
combined in a single device.133,134
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Small clearly defined aggregates of noble metals can 
be produced with very precise and controlled methods, 
modulating the reaction conditions used in their prepara-
tion. Metals in nanoparticulate form might be of interest in 
treating leishmaniasis, owing to their ability to produce ROS. 
In particular, silver nanoparticles135 were found to inhibit the 
survival of amastigotes in host cells and, in the presence of 
UV light, the effect was more significant. L. tropica promas-
tigotes lost their shape, and their internal organelles were no 
longer distinguishable.135
Metal oxide nanoparticles, especially titanium dioxide 
(TiO
2
), silver oxide (Ag
2
O), zinc oxide (ZnO), magnesium 
oxide (MgO), and, more recently, selenium oxide (SeO
2
) 
nanoparticles, have been extensively explored, demonstrating 
a significant antibacterial activity.136 Among metals, the high-
est antileishmanial activity was observed for nanoparticles 
composed of Ag, followed by Au, Ti, Zn, and Mg. Both 
UV and infrared irradiation increased the antileishmanial 
properties of all these nanoparticles. However, they were 
found to possess macrophages cytotoxicity. Selenium nano-
particles demonstrated less cytotoxic effect on uninfected 
macrophages but have stronger antiamastigote and antipro-
mastigote activities than SeO
2
.137
Another study focused on the development of six biocom-
patible nanoparticles of ZnO doped with different concentra-
tions of Cu and their in vitro efficacy against the Leishmania 
parasite.138 Especially those from ZnCuO to ZnCuO
5
 have 
been proposed against leishmaniasis, because of their 
biocompatibility and enhanced ROS yield: after irradiation, 
they generated measurable quantities of singlet oxygen. Simi-
larly, with Ag as dopant of the semiconductor, nanoparticles 
of zinc oxide demonstrated the production of ROS when 
activated by daylight and were able to kill L. tropica.139
More recently, two approaches were combined, using 
AmpB adsorbed on preformed spherical biogenic silver 
nanoparticles surface. AmB–Ag nanoparticles were more 
potent in inhibiting L. tropica in in vitro tests. Furthermore, 
the antileishmanial activity of the prepared nanoparticles was 
enhanced upon irradiation with visible light, which may be 
attributed to the formation of excess ROS by the released 
silver ions. The study limitation is the lack of the information 
about the amount of AmpB loaded.140
Among the inorganic nanomaterials, carbon compounds 
are attracting interest due to their excellent mechanical, 
thermal, and optical properties. Drugs may be covalently 
linked to carbon nanotubes (CNTs) or strongly absorbed by 
π–π stacking on their surface (eg, doxorubicin). However 
in its early ages in anti-Leishmania applications, a way of 
using multiwalled CNT to deliver covalently bound AmpB 
has been devised.141 Unusually, this product was obtained 
without using any condensing agent and was thought to 
be covalently linked via an ether bond instead of an amide 
bond. The intraperitoneal administration route led to a higher 
percentage suppression of parasites in the spleen with CNT–
AmpB (89.8%) than with AmpB (68.9%). Without any 
improvement in characterization, the same formulation was 
orally administered, resulting in antileishmanial activity in 
hamster spleen tissues.142
Due to their dimensions, similar to those of the inorganic 
components of calcified tissues, nanosized calcium phosphate 
materials are expected to have better bioactivity and biocom-
patibility than conventional materials. Furthermore, calcium 
phosphate is a cheap drug cargo that is chemically stable, 
composed of inorganic minerals native to the body, which 
can be metabolized as a nontoxic degradation product.143,144
The preparation of calcium phosphate nanoparticles 
loaded with AmpB has been reported.145 The method involved 
mixing two microemulsions containing, separately, calcium 
chloride and disodium phosphate, and sodium silicate in the 
presence of a surfactant. Nanoparticles ,200 nm in size, with 
an interesting AmpB loading of 11%, were obtained. In vivo 
efficacy of the formulation was assessed in a L. donovani-
infected golden hamster model. The in vivo activity of 
AmpB-loaded nanoparticles was stronger than that of mar-
keted formulations or AmpB suspension, which is the col-
lective outcome of higher internalization by macrophages via 
clathrin receptor-mediated phagocytosis and enhancement 
of Th1-biased immune response by nanoparticles, which 
ultimately targeted macrophages and retarded nonspecific 
distribution of AmpB. Furthermore, the calcium phosphate 
nanoformulation was able to release the encapsulated drug 
in a slow and sustained manner, with preferential accumu-
lation in macrophage-rich organs such as liver and spleen. 
A toxicity assessment study was also reported.145
Similar approach was also used to investigate the potential 
oral administration of pentavalent antimonials. Nanoparticle 
phosphate-based composites containing Sb(V) have been 
explored in terms of their in vitro activity.146 This system 
allowed the Sb(V) delivery into the cells in which the parasite 
is internalized, and the elevation of calcium concentrations 
inside the vacuoles might increase parasite apoptosis.
Covalently linked drug to polymers
In the nanosystems described earlier, the drug was always 
adsorbed, loaded, or entrapped in its native form. The 
covalent conjugation of drugs to an appropriate carrier is 
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another strategy used to deliver drugs to particular target 
sites. The development of specific carrier–drug conjugates 
was first proposed for the delivery of small hydrophobic drug 
molecules to their sites of action147 and has recently reached 
significant results in anticancer therapy with antibody–drug 
conjugates. These delivery systems basically comprise a 
water-soluble polymer, bearing a number of drug molecules 
covalently linked. The main advantages of this approach are 
1) increased water solubility of little soluble or insoluble 
drugs, therefore enhancing drug bioavailability; 2) protection 
of drugs from deactivation and relative activity preservation 
during circulation; and 3) most importantly, specifically drug 
targeting to the site of action. Unlike other approaches, in this 
case, the active agent must be considered as a prodrug that 
generates the activity only after release. For this reason, the 
role of linker between polymer and drug is of paramount 
importance, because it defines the mechanism for drug 
release (pH, enzyme derived, chemical reaction, and so on). 
Although many are undergoing the final phase of clinical 
trials and several polymer–protein conjugates have been 
approved by the FDA for clinical use, to date no polymer–
synthetic drug conjugate has been approved.148
Polymer–drug conjugates have been used for targeting 
macrophages and have already shown potential in antileish-
manial chemotherapy. HPMA is undoubtedly the best-known 
synthetic polymer exploited in macromolecular conjugates. 
It is water soluble and nonimmunogenic and has undergone 
clinical trials in the cancer field.149 In a detailed article, the 
synthesis of HPMA conjugate of AmpB obtained through a 
degradable GlyPheLeuGly linker is described. The linker was 
chosen as it is known to be cleaved by cathepsin B, which 
has been found in the PV.150 Its in vitro activity was compa-
rable to that of free AmpB and Fungizone, and although less 
active than AmBisome in in vivo experiments (though of a 
similar order), no signs of toxicity were recorded, even at 
the maximum used dose of 3 mg/kg AmpB equivalent used. 
It should be noted that this dose is above the reported 50% 
lethal dose (LD50) of 2.5 mg/kg for Fungizone. No signifi-
cant difference in antileishmanial activity was found using 
a similar but targeted conjugate with mannose.150 Further 
studies on polymer–drug conjugates in this field have not 
been reported, and clinical evaluation is thus lacking.
Another interesting natural polymer that can act as 
delivery platform and targeting scaffold simultaneously is 
hyaluronic acid.151 Recently, a versatile synthetic method to 
link pentamidine to hyaluronic acid, affording DL of up to 
33% (w/w), was presented. Assayed against the intracellular 
amastigote form of the parasite, the bioconjugate was more 
efficient than free drug in the internalization of infected 
macrophages but, at the same time, less cytotoxic.152
Novel products with antileishmanial 
activity combined into nanocarriers
The need for alternative treatments, in particular to reduce 
the duration of clinical treatment, led to a program to screen 
natural products for potential use in leishmaniasis therapy, 
as recent reviews report,153–156 and also to the screening of 
currently available medicines with potential use in VL. 
In parallel, quantitative structure–activity relationship 
(QSAR) study has been used to identify new organic com-
pounds with stronger activity.157 Another approach examined 
the role played by known active molecules in medicinal 
plants traditionally used against leishmaniasis, as well as in 
documented plants that have yet to be explored.158–161
Several active agents from different chemical classes 
are also reported to have in vitro antileishmanial activity. 
The more promising candidates appear to be the nitroimida-
zoles, quinoline scaffold-based derivatives such as indolyl 
quinoline analogs, naphthoquinones, the cytotoxic drug 
doxorubicin, and also antimicrobial peptides.108,162 A recent 
review clearly summarizes these results.163 Disulfiram, 
a drug extensively used to treat alcoholism, has recently been 
reported to be active at nanomolar concentrations against the 
intracellular amastigotes of L. donovani.164 Although clinical 
trials have not yet been carried out to assess the efficacy of 
disulfiram as monotherapy or in combination to treat different 
types of leishmaniasis, the implementation of a clinical trial 
is feasible, since disulfiram is a known and approved drug 
and, furthermore, is administered orally.
OlPC is a structural analog of MF. The in vitro efficacy 
of OlPC against the intracellular amastigotes of different 
Leishmania spp. was similar to the profile of MF, with 
IC
50
 values in the low micromolar range, except for L. major 
and L. braziliensis.165 When tested on a VL hamster model 
with L. infantum, OlPC was found to be more potent than 
MF after multiple or single oral dosing. Furthermore, short 
oral treatment with OlPC improves clinical signs of canine 
L. infantum leishmaniasis.166 The pharmacokinetic profiles 
of OlPC, administered either in water or as a liposomal 
preparation, have also been reported recently.167
Natural agent, namely andrographolide, is a diterpenoid 
lactone extracted from the leaves of Andrographis paniculata, 
with strong antiparasitic and antileishmanial activity.168 Fur-
ther progress was achieved upon studying andrographolide’s 
behavior regarding resistance, with PLGA nanoparticles 
loaded with andrographolide and stabilized with vitamin 
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E TPGS.169 Nanoparticles were delivered into macrophage 
cells infested with sensitive and drug-resistant amastigotes 
of L. donovani parasites. Antileishmanial activity was 
found to be significant for the nanoparticles with TPGS at 
about one-tenth of the free drug dosage and one-third of the 
nanoparticles without TPGS dosage. When andrographolide 
was incorporated in TPGS nanoparticles, the selectivity of 
andrographolide increased eightfold in resistant cells.169
Recently, the same approach was used to deliver oleanolic 
acid (OA), a naturally occurring pentacyclic triterpene with 
antileishmanial activity.170 In vivo evaluation indicated that 
OA suppressed the amastigote burden in the spleen after 
the fourth dose (67.69%±4.12%), whereas the percentage 
of suppression was increased to 98.82%±1.92% in the case 
of OA PLGA nanoformulation.
A further example concerns bisnaphthalimidopropyl 
(BNIP) derivatives, which exert significant antiproliferative 
activity on L. infantum.171 Encapsulation of BNIP aminooc-
tane derivative into PLGA nanoparticles resulted in a reduc-
tion of aspecific toxicity and in the 80% increase of in vivo 
efficiency on L. infantum compared to free drug.172 This 
nanoformulation remained active after oral administration 
in infected BALB/c mice.
Artemisinin, a potent drug used against Plasmodium 
falciparum malaria, potentially possesses antileishmanial 
activity, although bioavailability and stability are low.173 
Encapsulating artemisinin into PLGA nanoparticles reduced 
the free drug macrophage toxicity, increasing leishmanicidal 
activity.174 Furthermore, NO production may intercede in 
the antileishmanial effect of the nanoformulations. Unfor-
tunately, the curative effect was not as high as the standard 
liposomal AmpB formulation.175
Curcumin (diferuloylmethane), the main yellow bioactive 
component of turmeric, has been shown to have a wide 
spectrum of biological action, including leishmanicidal 
activity in vitro.176 Different approaches have been proposed 
to deliver curcumin. A particular type of prodrug-based 
approach, named “squalenoylation” has been proposed.177 
In this approach, the derivatization of small molecules by 
conjugation with a squalene moiety enables conjugates to be 
produced that spontaneously self-assemble into 60–300 nm 
nanoparticles. Although to date it has mainly been applied 
in the anticancer field,178 a squalenoyl prodrug of curcumin 
was recently investigated in promastigote and amastigote 
forms of L. donovani and showed enhanced activity vs 
the parent drug.179 Recently, PLGA nanoparticles loaded 
with curcumin (nanocurcumin) were proposed to support 
MF in exerting leishmanicidal effect at a subcurative dose 
through immunomodulation. Nanocurcumin monotherapy or 
combination therapy with MF did not exhibit any hepato- or 
nephrotoxicity effect.180
Compound 8-hydroxyquinoline (8-HQN) and its 
derivates have been experimentally evaluated in different 
studies as chemotherapeutic agents with interesting anti-
leishmaniasis activity.181,182 Recently, polymeric micelle 
system was exploited to deliver 8-HQN.183 After daily 
subcutaneous injections for 15 days in L. infantum-infected 
mice, the treated group showed a more marked reduction 
in the parasite load than the control group. The formulation 
was highly effective in treating the disease, more so than free 
8-HQN or AmpB; the highest levels of nitrite were found in 
the 8-HQN/M-treated mice, together with a significant Th1 
immune response.
In a different approach NPC1161, a model 8-amino-
quinoline drug with antileishmanial activity was conjugated 
with HPMA and targeted with N-acetylmannosamine.184
Inorganic carrier such as CNTs was recently used to 
deliver betulin, a pentacyclictriterpenoid with antileishmanial 
properties.185 Counting the amastigote cells inside the infected 
macrophage cells using a microscope, a dose-dependent 
response was observed with betulin and with CNT-linked 
betulin, whereas CNT alone did not show any antileishmanial 
effect. In addition, CNT was seen to downregulate the activity 
of P-gp efflux, which would help to increase the bioavail-
ability of any drug incorporated into the carrier system and 
overcome resistance mechanisms. However, toxicity data are 
still limited, and further effort will be required to evaluate in 
depth not only the potency but also the in vivo fate of these 
formulations (eg, biodistribution and elimination from the 
body).185 A complete toxicological evaluation must also be 
made before they can be administered safely.
Discussion
At present, only a small number of antileishmanial drugs 
are available for clinical use: three injectables and the sole 
orally administrable MF. There is thus a pressing need to 
develop other antileishmanial drugs as each of the available 
drugs suffers from various drawbacks (toxicity, repeated dose 
requirement, and so on).
To reduce dosage, enable improved release, and promote 
high drug concentrations in the intracellular (macrophage) 
vesicle where Leishmania is hosted, DDSs may play a cru-
cial role. Colloidal carriers can also protect drugs against 
extracellular degradation, improving the pharmacokinetic 
profile of the active agent. The most significant result is 
the case of AmBisome, which has significantly improved 
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VL treatment, as it provides almost complete eradication of 
parasite burden, with minor toxic effects. However, the cost 
of this lipid formulation is a severe deterrent, in the light of 
the need to provide a reasonably priced therapeutic option to 
third world countries. Resistance to AmpB has not yet been 
observed in clinical practice, although it has been reported 
in in vitro study.29 Thus, the DDS approach had not been yet 
evaluated on resistant lines.
Since AmpB is currently the most potent antileishmanial 
agent, the majority of efforts in nanotechnology have been 
addressed to improving its specificity, reducing its adverse 
effects, and in some cases, using noninvasive route. For this 
reason, in this section, we critically evaluate and discuss the 
role and advantages that may be played by innovative AmpB 
delivery systems. The principal systems, methods and results, 
described in the text, are summarized in Table 2. Considering 
the structure, the majority of the systems comprise polymeric 
nanoparticles or nanocapsules of size (100–300 nm) greater 
than that of AmBisome. As far as, the stability of the carrier 
is concerned, the polymeric systems are much more stable 
than liposomes, and from the regulatory standpoint, the use 
of polymers that are already approved by FDA/EMA may 
reduce the need for toxicological studies, in comparison 
to other systems. PLA and PLGA are widely used in 
many FDA-approved drug products.96 DL is an important 
parameter to predict the strength of an approach. If drug 
capacity is ,4%–5% (w/w) of the carrier material, either 
the quantity of drug administered will not be sufficient to 
achieve a pharmacologically active concentration in the rel-
evant body compartment capable of eradicating the parasite 
burden, or the amount of carrier material required will be 
too large, leading to toxicity.186 The hydrophobic core of 
PLGA nanoparticle (NP) and LPNP facilitates the loading 
of AmpB, which can reach significant levels. Another issue 
in nanoparticle systems that may lead to lower activity, and 
potentially to more toxicity, is the rapid release or premature 
“burst release” of the encapsulated drug. This phenomenon 
is not frequent in the case of AmpB, because in polymeric 
NP, only a small fraction of the drug is present in the free, 
monomeric form, the majority remaining superaggregated 
and associated with the delivery system.97
The majority of nanostructures achieved interesting 
ranges of DL (up to 44% in one case). Passive or “natural” 
targeting, since the MPS cells are considered to be the main 
target for therapeutic interventions in leishmaniasis, is a 
mechanism that may be used to enhance drug concentra-
tion, reducing aspecific toxicity (hematotoxicity and kidney 
toxicity). Nevertheless, the active targeting approach (using 
mannose, stearylamine, mannan, and antibody fragments) 
appears to slightly increase the uptake in liver and spleen 
lesions. In particular, the surface charge of LPNPs created 
by stearylamine enhanced uptake by macrophages, demon-
strating interesting immunoadjuvant properties. In LPNP, 
the lipid component of the formulation also behaves as a 
targeting agent, while in the majority of formulations, surface 
decoration was preferred. In the latter case, clearly illustrated 
by the use of antibodies, difficulties may arise because there is 
as yet no clear information concerning the “optimum” range 
of ligand characteristics (ie, valency, avidity, conformation, 
and packing) on the surface of nanocarriers that results in 
reproducible target binding and internalization. Manufac-
turing these products may be challenging; this is clearly of 
great practical importance, as is shown by the lack of actively 
targeted liposomes on the market for cancer therapy.
Owing to their complexity, site-directed DDSs will always 
require full and in-depth characterization before being 
proposed for industrial development and manufacturing. 
Especially when novel components (lipids, lipid polysaccha-
rides, and so on) with unknown toxicological properties are 
added to the formulation, or when too many complex steps are 
required, industrial interest decreases sharply. Regarding cost-
effectiveness, PLGA, a pharmaceutically accepted polymer, 
including from the regulatory standpoint, is more advantageous 
than more “sophisticated” systems, although these may be of 
interest, as is the case of L-Psomes or targeted systems.
Nevertheless, it is important to notice that each study, 
able to combine novelty and promising in vivo results, should 
be compared with the best treatment available (AmBisome). 
This comparison was done only in 44% of the studies reported 
in Table 2.
Also molecular conjugates, typically prepared to increase 
drug pharmacokinetic profile, did not significantly improve 
the AmpB antileishmanial activity.150 A remarkable review 
by Duncan148 reflects very clearly on the current status of 
polymer therapeutics, the major issues concerned, and future 
opportunities.
Conclusion
Bearing in mind the results obtained in some clinical trials 
where a single-course iv therapy of 10 mg/kg AmBisome 
was found to give a 98% cure,26 the space for robust and 
market-oriented innovation seems to be represented mainly 
by the delivery of AmpB by oral route, but this delivery must 
be directed in targeted tissues to elicit its pharmacological 
effect while reducing its nephrotoxicity and infusion-related 
side effects.
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Even if it remained difficult to select and design an 
appropriate formulation to improve AmpB oral absorption, 
some novel DDSs have emerged as effective. In particular, 
lipid cochleates and an SLN formulation (AmbiOnp) appear 
very promising, not least because they are already involved 
in industrial development. Both approaches provide high DL-
reduced AmpB toxicity and production protocols that avoid 
expensive compounds or processes. Further improvement 
could involve a polymer such as chitosan, which combines 
bioadhesion and absorption-enhancing properties, to prolong 
contact between the DDS and the mucosa, increasing the 
amount of AmpB that can be absorbed.
In recent years, material sciences and biomedical sciences 
have produced numerous new systems and materials with 
the potential to treat disease. However, two major limita-
tions must be borne in mind. First, as the recent literature 
concerning DDSs shows, there is a flourishing strain of 
articles in which increased complexity appears to be seen as 
an advantage, without any real justification in terms of the 
balance between complexity and feasibility. Second, complex 
delivery systems obviously cost more to develop and manu-
facture than do conventional therapeutic agents. The resulting 
higher prices may only be acceptable if the performance of 
these systems is sufficiently increased, thereby reducing the 
treatment period and overall cost, leading to savings to the 
health care system. It is becoming ever more imperative to 
formulate standards for system characterization, and robust 
means of comparative testing, so as to facilitate close and 
critical analysis of proposed strategies. Further efforts and 
investments will still be necessary for this approach to 
achieve greater clinical applicability in humans.
Meanwhile, with regard to the identification of novel drugs, 
there can be no doubt that the availability of the complete 
genome sequence of Leishmania has given the scientific com-
munity the possibility for large-scale analysis, which may lead 
to a better understanding of the parasite’s biology and conse-
quent identification of novel drug targets.187 Furthermore, the 
use of powerful CRISPR–Cas9 techniques of genome editing 
is now making it possible to accelerate the characterization of 
Leishmania genes, so as to develop new drugs, diagnostics, and 
vaccines.188 From another standpoint, the medicinal chemistry 
approach continues to improve “old drugs”, suggesting novel 
AmpB derivatives with high activity and increased safety.189
However, since the goal is to eliminate parasitic infec-
tions, a “discovery science” for the development of drugs and 
diagnostics must be conducted on the global stage, involving, 
in the local context, scientists, clinicians, regulators, and 
health ministries in disease-endemic countries. Furthermore, 
“implementation science” must take place in the local 
context. To achieve the goal, it is of fundamental importance 
to involve multidisciplinary teams, including pharmaceutical 
and medical scientists, policymakers, social scientists, health 
administrators, and communication scientists, working 
together in new ways.190
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